Evaluation of Liraglutide 3.0mg in Patients With Poor Weight-loss and a Suboptimal Glucagon-like Peptide-1 Response

NCT03341429 · Completed

Last updated 2026-05-28

This clinical trial tested the medication liraglutide at a 3.0mg dose in adults with obesity who had poor weight loss and a weak response to a natural gut hormone called GLP-1.

Status Completed The study has finished.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design Randomized, quadruple-blind treatment study

Participants 70 people

Who can join Ages 18–64 · all sexes

Timeline Started 2018-08 · est. completion 2020-06

Where 1 site · United Kingdom

What this study is testing ClinicalTrials.gov NCT03341429 ↗

Description as written by the study sponsor.

A double-blinded, randomised, placebo-controlled trial of liraglutide 3.0 mg in patients with poor weight-loss and a suboptimal glucagon-like peptide-1 response following bariatric surgery

Treatments tested

Liraglutide Pen Injector [Saxenda] also known as Saxenda Drug

Daily injection of GLP-1 agonist (liraglutide 3.0 mg) for obese patients presenting poor weight loss (\<20%) after bariatric surgery and suboptimal GLP-1 levels.
Placebo Drug

Daily subcutaneous injection

Main thing measured	%WL
Sponsor	University College, London
Conditions studied	Obesity
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT03341429 ↗